Compare Novartis AG (NVS) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Block Inc — how do they compare? Novartis AG trades at $143.28 (market cap $268.57B), while Block Inc trades at $77.07 (market cap $45.20B). The key difference: Novartis AG is far larger — about 5.9× Block Inc's market cap, and Novartis AG pays a 3.31% dividend while Block Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Block Inc for 78 Days on average.
| NVS | XYZ | |
|---|---|---|
Market Cap | $268.57B | $45.20B |
Volume | 1,532,573 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $168.62 | $84.85 |
52-Week Low | $121.80 | $49.04 |
Typical Hold Time | 82 Days | 78 Days |
Enterprise Value | $309.89B | $40.10B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Block (XYZ) trades at $77.09, up 1.34% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q1 and Q2 2026 earnings beats but faces profitability challenges with a net margin of just 1.43%. Recent developments include expanding Square and Cash App partnerships with Apple and Workday, while pursuing a national trust bank charter to reduce third-party banking costs.
The stock offers 26% upside to the $97.47 consensus target with strong analyst support (77% buy ratings), though high P/E of 134.34 raises valuation concerns. Key risks include declining net income margins, insider selling activity, and competitive fintech pressures. The upcoming Q3 2026 earnings report on November 3rd will be critical for validating growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
